Precision Nanomedicine · Published 2026-02-17 · DOI 10.33218/001c.157822
Brain-linked pathologies such as neurodegenerative diseases, malignant brain tumors, cerebrovascular and infectious neuropathologies remain difficult to diagnose and treat because of the restrictive and disease-dependent nature of biological barriers in the central nervous system. Although nanotechnology has achieved considerable preclinical success, the clinical implementation of nanoparticle-based brain treatments has been inconsistent, and a significant gap exists between experimental models and clinical reality. Nanoparticle strategies to overcome delivery barriers are critically analyzed with particular emphasis on theranostic systems and emerging biomimetic approaches. In addition to categorizing nanoparticles by class, we incorporate blood-brain barrier (BBB) structural and functional heterogeneity along with post-BBB transport constraints, including interstitial diffusion, cellular uptake variability, and intracellular trafficking, together with nanoparticle physicochemical design parameters such as size, surface charge, and functionalization, to explain why delivery outcomes are disease- and stage-dependent. Major nanoparticle platforms, including polymeric, liposomal, dendrimeric, metallic, carbon-based, and biomimetic systems, are being considered for Alzheimer’s disease, Parkinson’s disease, glioblastoma, stroke, and infectious brain pathologies. Integration of recent preclinical findings with emerging clinical trial evidence indicates that immune clearance, pharmacokinetic variability, limited tissue distribution, manufacturing complexity, and regulatory challenges are key contributors to translational failure. To address the trade-offs between multifunctional complexity and clinical feasibility, a disease-informed and regulation-aware framework is proposed to guide future nanoparticle development. Advancing brain nanomedicine will require coordinated progress across materials science, neuropharmacology, and translational research to move from proof of concept toward effective patient therapies.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →